Table 2.
Characteristics of the PTC patients before and after PSM matching.
| Characteristic, number (%) | Before PSM Matching |
After PSM Matching |
||||
|---|---|---|---|---|---|---|
| control (n = 2508) | PTC-with-HPT (n = 27) | p-value | control (n = 103) | PTC-with-HPT (n = 26) | p-value | |
| Sex, female | 1977 (78.8) | 18 (66.7) | 0.15 | 75 (72.8) | 18 (69.2) | 0.81 |
| Age at diagnosis (year)b | 43.6 [33; 53] | 51.9 [39; 61] | 0.002a | 47.6 [39; 58] | 50.9 [39; 60] | 0.25 |
| Tumor size (cm)b | 2.3 [1.2; 3.0] | 1.4 [0.5; 1.7] | <0.001a | 1.4 [0.5; 1.9] | 1.3 [0.5; 1.6] | 0.97 |
| Multifocality | 621 (24.8) | 6 (22.2) | 1.00 | 20 (19.4) | 6 (23.1) | 0.79 |
| Histology | ||||||
| Classic PTC | 2099 (83.7) | 20 (74.1) | 0.19 | 91 (88.3) | 19 (73.1) | 0.06 |
| Follicular variant PTC | 375 (15.0) | 7 (25.9) | 12 (11.7) | 7 (26.9) | ||
| Others | 34 (1.4) | 0 | 0 | 0 | ||
| TNM stage | ||||||
| Stage I | 1747 (69.7) | 23 (85.2) | 0.09 | 90 (87.4) | 23 (88.5) | 1.00 |
| Stage II | 233 (9.3) | 1 (3.7) | 4 (3.9) | 0 | ||
| Stage III | 194 (7.7) | 1 (3.7) | 4 (3.9) | 1 (3.8) | ||
| Stage IV | 334 (13.3) | 2 (7.4) | 5 (4.9) | 2 (7.7) | ||
| Operative method | ||||||
| Total thyroidectomy | 2173 (86.6) | 19 (70.4) | 0.02a | 72 (69.9) | 18 (69.2) | 1.00 |
| Less than total | 335 (13.4) | 8 (27.6) | 31 (30.1) | 8 (30.8) | ||
| 1M-Post-op Tg (ng/mL)b | 158.8 [0; 18.3] | 35.2 [0; 18.3] | 0.64 | 30.7 [0; 22.6] | 36.7 [1.5; 19.8] | 0.67 |
| Post-op131I dose (mCi)b | 130.8 [30; 150] | 99.3 [0; 100] | 0.04a | 94.6 [0; 105] | 103.1 [0; 108] | 0.92 |
| Secondary primary cancer | 178 (7.1) | 2 (7.4) | 0.72 | 6 (5.8) | 2 (7.7) | 0.66 |
| Follow-up period (year)b | 9.5 [3.8; 14.3] | 7.9 [3.9; 11.9] | 0.32 | 8.9 [3.5; 12.3] | 7.7 [3.5; 11.8] | 0.50 |
Abbreviations: 1M-Post-op Tg: one-month postoperative serum thyroglobulin level; Post-op 131I dose: postoperative 131I cumulative dose.
a
Statistical significance.
b
Presented as mean [quartiles].